Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8186259 | 1.00 | HRH3 (0.53) | HRH3SIGMAR1CHRM2CHRM1TSHR | |
| SCHEMBL10092689 | 0.98 | HRH3 (0.50) | HRH3SIGMAR1CHRM2CHRM1TSHR | |
| SCHEMBL12396793 | 0.93 | HRH3 (0.46) | HRH3SIGMAR1CHRM2CHRM1TSHR | |
| SCHEMBL24742908 | 0.91 | HRH3 (0.47) | HRH3SIGMAR1CHRM2CHRM1TSHR | |
| SCHEMBL22456382 | 0.91 | HRH3 (0.49) | HRH3SIGMAR1CHRM2CHRM1TSHR | |
| SCHEMBL10162384 | 0.90 | HRH3 (0.46) | HRH3SIGMAR1CHRM2CHRM1TSHR | |
| SCHEMBL10092700 | 0.88 | HRH3 (0.41) | HRH3SIGMAR1CHRM2CHRM1TSHR | |
| SCHEMBL10162381 | 0.87 | HRH3 (0.43) | HRH3SIGMAR1CHRM2CHRM1TSHR | |
| SCHEMBL6743387 | 0.86 | SIGMAR1 (0.46) | HRH3SIGMAR1CHRM2CHRM1TSHR | |
| SCHEMBL14453902 | 0.86 | HRH3 (0.41) | HRH3TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190593-A1 | SPLICEOSOME MUTATIONS AND USES THEREOF | EISAI R&D MAN CO LTD (JP) | 2020-06-18 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| WO-2007134449-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | HRH3 2314/4885SIGMAR1 2967/4885CHRM2 1029/4885 |
| US-20200190593-A1 | SPLICEOSOME MUTATIONS AND USES THEREOF | SF3B1, SF3B5, SF3A1 | HRH3 3203/4885SIGMAR1 4126/4885CHRM2 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.